Should You Buy Viking Therapeutics Inc (VKTX) Stock on Monday?

Viking Therapeutics Inc (VKTX) stock is higher by 7.41% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Viking Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VKTX!

See Full VKTX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With VKTX Stock Today?

Viking Therapeutics Inc (VKTX) stock is trading at $22.89 as of 12:32 PM on Monday, Jun 5, a rise of $0.61, or 2.74% from the previous closing price of $22.28. The stock has traded between $22.33 and $23.38 so far today. Volume today is less active than usual. So far 683,942 shares have traded compared to average volume of 3,164,018 shares.

More About Viking Therapeutics Inc

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. Click Here to get the full Stock Report for Viking Therapeutics Inc stock.